Molecular Partners AG

NASDAQ:MOLN

Biotechnology

Healthcare
$2.67 +0.77%

+$0.03 today

Market cap
$100.28M
Beta
0.71
P/E (TTM)
-2.0
EPS (TTM)
-$1.55
52W Low $3.41High $5.36

Volume 0.00M

Average 0.00M

MOLN Capital Expenditures

Cash spent on property, plant, equipment, and other long-term assets.

Molecular Partners AGNASDAQ: MOLN

Capital Expenditures · Q1 FY2026 · quarter ended Mar 2026

Capital expenditures turns positive

Q1 FY2026 capital expenditures was CHF 0, compared with -CHF 448K a year earlier. Trailing-twelve-month capital expenditures was -CHF 333.55K. Over 3 fiscal years it compounded at -20.4% a year.

Context

  • Capital expenditures grew in size in 1 of the last 3 fiscal years.

What to watch

Whether quarterly capital expenditures holds near CHF 0 or moves back toward the trailing-twelve-month quarterly average of -CHF 83.39K.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
CHF 0+100.0% QoQ
Last fiscal yearDec 2025
-CHF 714K-1.2% YoY
LTMMar 2026
-CHF 333.55K-67.9% YoY
Capital Expenditures past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+100.0%——
1 year-1.2%——
3-year CAGR-20.4%——
5-year CAGR——
10-year CAGR——

Capital Expenditures history

CHF · from the cash flow

Latest · FY2025
(714K) CHF
Year-over-year change
+1.2%

Capital Expenditures vs competitors

How MOLN compares with its peers on the latest reported figures

  • Peers report in different currencies, so capital expenditures is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -67.9% is the 2nd highest of 7, against a peer median of -79.0%.
  • Over three fiscal years its annual growth of -20.4% compares with a peer median of -62.7%.
MOLN Competitors
Capital Expenditures for MOLN and competitors
Company Period LTM YoY 3-year CAGR% of revenue
NKTXNkarta, Inc.LTM Mar 2026$1.1M USD-76.8%-70.5%—
MOLNMolecular Partners AGLTM Mar 2026CHF 333.55K CHF-67.9%-20.4%—
ALECAlector, Inc.LTM Mar 2026$139K USD-81.3%-78.5%0.8%
PEPGPepGen Inc.LTM Mar 2026$139K USD-75.6%-58.7%—
MISTMilestone Pharmaceuticals Inc.LTM Mar 2026$68.98K USD+76.9%+3.5%3.9%
RANIRani Therapeutics Holdings, Inc.LTM Mar 2026$52K USD-82.7%-62.1%1.6%
CRDFCardiff Oncology, Inc.LTM Mar 2026$44K USD—-63.3%8.4%
ELTXElicio Therapeutics, Inc.LTM Mar 2026$16K USD-81.6%-71.0%—
CRBPCorbus Pharmaceuticals Holdings, Inc.LTM Mar 2026$13K USD—-19.6%—
Peer median (excluding MOLN) —-79.0%-62.7%2.8%

Competitors are the stored peer set for MOLN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

CHF
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(63.79M)117.85M(61.98M)(54.04M)(61.65M)
Depreciation & Amortization2.57M2.39M2.42M2.37M2.14M
Deferred Income Tax2K002K2K
Stock-Based Compensation4.09M5.09M5.21M4.11M4.42M
Change in Working Capital(34.67M)(6.01M)(6.01M)(3.8M)1.16M
Accounts Receivables(23.37M)25.26M(933K)(347K)463.2K
Inventory21.72M(19.93M)000
Accounts Payables1.66M(5.34M)(812K)524K62.08K
Other Working Capital(34.67M)(6.01M)(4.27M)(3.97M)630.33K
Other Non-Cash Items848K(753K)1.36M(7.88M)2.67M
Operating Cash Flow(90.95M)118.57M(59.01M)(59.25M)(51.26M)
Capital Expenditures(1.31M)(1.42M)(575K)(723K)(714K)
Acquisitions (Net)374K0000
Purchases of Investments(88.88M)(299.42M)(277.83M)(240.05M)(66.28M)
Sales of Investments67.88M199.22M319.44M277.02M137.81M
Other Investing Activities(304K)494K3.83M4.22M1.73M
Investing Cash Flow(22.24M)(101.12M)44.64M40.49M72.55M
Debt Repayment(1.18M)(1.19M)(1.2M)(1.21M)(1.21M)
Common Stock Issued51.49M250K31K17.34M63K
Common Stock Repurchased0(631K)000
Dividends Paid00000
Other Financing Activities267K250K31K(1.7M)0
Financing Cash Flow50.58M(1.57M)(1.17M)14.43M(1.15M)
Effect of Forex Changes701K258K(5.1M)894K(1.36M)
Net Change in Cash(61.91M)16.13M(20.64M)(3.44M)18.78M
Free Cash Flow(92.26M)117.15M(59.81M)(59.97M)(51.97M)

Molecular Partners AG

NASDAQ:MOLN

Intrinsic Alpha fair value

Locked

Current Price

$2.67

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.